Beta-blocker therapy at discharge was associated with reduced 1-year mortality in acute coronary syndrome patients with LVEF ≤ 40%, but the effect was unclear for LVEF > 40%.
Does beta-blocker therapy at discharge reduce 1-year mortality in acute coronary syndrome patients?
Tasa de eventos absoluta: 0% vs 0%
Aims: While the beneficial effect of beta-blocker (BB) therapy for acute coronary syndrome (ACS) patients with a left ventricular ejection fraction (LVEF) of 40% is established, its role in those with LVEF > 40% is controversial. We assessed the relationship between BB therapy at discharge and 1-year mortality according to LVEF in a large contemporary acute coronary syndrome (ACS) cohort.
Maeder et al. (Sat,) reported a other. Beta-blocker therapy at discharge was associated with reduced 1-year mortality in acute coronary syndrome patients with LVEF ≤ 40%, but the effect was unclear for LVEF > 40%.